Patents by Inventor Hiroaki Inagaki

Hiroaki Inagaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11446287
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: September 20, 2022
    Assignee: Opna Immuno-Oncology SA
    Inventors: Wayne Spevak, John Buell, Zuojun Guo, Hiroaki Inagaki, Yongil Jin, Phuongly Pham, Songyuan Shi, Jack Walleshauser, Jeffrey Wu, Guoxian Wu, Chao Zhang, Jiazhong Zhang, Ying Zhang
  • Publication number: 20210315872
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 14, 2021
    Inventors: Wayne Spevak, John Buell, Zuojun Guo, Hiroaki Inagaki, Yongil Jin, Phuongly Pham, Songyuan Shi, Jack Walleshauser, Jeffrey Wu, Guoxian Wu, Chao Zhang, Jiazhong Zhang, Ying Zhang
  • Publication number: 20210315869
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, R3, R4, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: April 1, 2021
    Publication date: October 14, 2021
    Inventors: Aaron Albers, Zuojun Guo, Hiroaki Inagaki, Phuongly Pham, Hannah Powers, Wayne Spevak, Jack Walleshauser, Jiazhong Zhang, Ying Zhang
  • Publication number: 20210163464
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: June 3, 2021
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta
  • Patent number: 11020398
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 1, 2021
    Assignee: ArQule, Inc.
    Inventors: Craig Bates, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • Patent number: 11020400
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: June 1, 2021
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Publication number: 20210145837
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Applicant: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Patent number: 10933065
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 2, 2021
    Assignee: ArQule Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Patent number: 10851092
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 1, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta
  • Publication number: 20200061071
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 27, 2020
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Publication number: 20200039974
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 28, 2017
    Publication date: February 6, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta
  • Publication number: 20190358233
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 28, 2019
    Inventors: Craig BATES, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • Publication number: 20190192520
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Patent number: 10245263
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 2, 2019
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Publication number: 20180055846
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Inventors: Craig BATES, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • Publication number: 20170182053
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 29, 2017
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Patent number: 9630968
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 25, 2017
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Patent number: 8952010
    Abstract: A compound represented by the following formula (I) or a salt thereof: wherein R represents a hydrogen atom, a hydroxy group, or a halogen atom Ar1 represents a bicyclic heterocyclic group represented by the following formula: ?and Ar2 represents a bicyclic heterocyclic group represented by the following formulae:
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: February 10, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Tetsunori Fujisawa, Masao Itoh, Aki Yokomizo, Toshifumi Tsuda, Saito Higuchi, Biswajit Das, Rita Katoch, Dilip J. Upadhyay
  • Publication number: 20140187542
    Abstract: A compound represented by the following formula (I) or a salt thereof: wherein R represents a hydrogen atom, a hydroxy group, or a halogen atom Ar1 represents a bicyclic heterocyclic group represented by the following formula: and Ar2 represents a bicyclic heterocyclic group represented by the following formulae:
    Type: Application
    Filed: February 6, 2012
    Publication date: July 3, 2014
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroaki Inagaki, Tetsunori Fujisawa, Masao Itoh, Aki Yokomizo, Toshifumi Tsuda, Saito Higuchi, Biswajit Das, Rita Katoch, Dilip J. Upadhyay
  • Publication number: 20140142096
    Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 22, 2014
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi